CACNA1D-Related Channelopathies: From Hypertension to Autism.

This review looks at changes in a gene called CACNA1D that can cause various health problems, including autism. These gene changes affect how calcium moves in and out of cells, which is important for brain function. Researchers found that some rare gene variations can cause developmental delays and autism-like symptoms. The good news is that existing blood pressure medications might help treat these conditions, though more research is needed.

This comprehensive review examines CACNA1D gene variants and their association with various conditions including autism spectrum disorders. CACNA1D encodes calcium channel subunits critical for neurological function. The review discusses how rare de novo variants can cause neurodevelopmental disorders of variable severity, with electrophysiological studies showing these variants enhance channel activity. The authors suggest potential treatment approaches using existing calcium channel blockers (dihydropyridines) approved for hypertension as off-label therapy.

The review highlights the increasing identification of CACNA1D variants through advanced sequencing and emphasizes the need for personalized treatment approaches based on genotype-phenotype correlations.

CACNA1D genetic testing may help identify causes of autism and neurodevelopmental disorders. Personalized treatment with calcium channel blockers could be considered for affected individuals, though this requires careful medical supervision and further research to establish safety and efficacy.

This is a narrative review without systematic methodology. Sample sizes and specific clinical outcomes are not quantified. Evidence for treatment effectiveness comes from limited in vitro studies and individual case reports rather than controlled trials.

Tightly controlled Cainflux through voltage-gated Cachannels (Cavs) is indispensable for proper physiological function. Thus, it is not surprising that Cav loss and/or gain of function have been implicated in human pathology. Deficiency of Cav1.3 L-type Cachannels (LTCCs) causes deafness and bradycardia, whereas several genetic variants of CACNA1D, the gene encoding the pore-forming α1 subunit of Cav1.3, have been linked to various disease phenotypes, such as hypertension, congenital hypoglycemia, or autism. These variants include not only common polymorphisms associated with an increased disease risk, but also rare de novo missense variants conferring high risk.

This review provides a concise summary of disease-associated CACNA1D variants, whereas the main focus lies on de novo germline variants found in individuals with a neurodevelopmental disorder of variable severity. Electrophysiological recordings revealed activity-enhancing gating changes induced by these de novo variants, and tools to predict their pathogenicity and to study the resulting pathophysiological consequences will be discussed. Despite the low number of affected patients, potential phenotype-genotype correlations and factors that could impact the severity of symptoms will be covered. Since increased channel activity is assumed as the disease-underlying mechanism, pharmacological inhibition could be a treatment option.

In the absence of Cav1.3-selective blockers, dihydropyridine LTCC inhibitors clinically approved for the treatment of hypertension may be used for personalized off-label trials. Findings from in vitro studies and treatment attempts in some of the patients seem promising as outlined. Taken together, due to advances in diagnostic sequencing techniques the number of reported CACNA1D variants in human diseases is constantly rising. Evidence from in silico, in vitro, and in vivo disease models can help to predict the pathogenic potential of such variants and to guide diagnosis and treatment in the clinical practice when confronted with patients harboring CACNA1D variants.